Skip to main content
SpringerLink
Log in

Eignung von Metipranolol für die Therapie des Glaukoms aus pharmakologischer Sicht

Pharmakologische Eigenschaften von Metipranolol bei der Glaukomtherapie

  • Chapter
Metipranolol

  • 16 Accesses

Zusammenfassung

Im Titel dieses Beitrages spreche ich von der Eignung von Metipranolol; ich meine damit die Brauchbarkeit dieses Beta-Rezeptoren- blockers für die topische Anwendung am Auge, beurteilt aufgrund seiner pharmakologischen Eigenschaften, nicht aber in Bezug auf die Wirksamkeit aus klinischer Sicht. Beta-Rezeptorenblocker werden nunmehr seit 15 Jahren für die Indikation Glaukom mit Erfolg angewendet und an der grundsätzlichen Wirksamkeit aller auf dem Markt befindlichen Beta-Blocker besteht für diese Therapieform, so glaube ich, kein Zweifel mehr.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Philipps, C. I., Howitt, G., Rowlands, D. J.: Propranolol as ocular hypotensive agent. Brit. J. Ophthalmol. 51, 111–116 (1967).

    Google Scholar 

  2. Wettrell, K., Pandolfi, M.: Propranolol vs. acetazolamide. A long-term double-masked study of the effect on intraocular pressure and blood pressure. Arch. Ophthalmol. 97, 280–283 (1979).

    Article  PubMed  CAS  Google Scholar 

  3. McDonald, M., et al.: Comparison of ocular hypotensive effects of acetazolamide and atenolol. Br. J. Ophthalmol. 61, 345–348 (1977).

    Article  Google Scholar 

  4. Elliot, M. H., Gullen, P. M., Philipps, C. I.: Ocular hypotensive effect of atenolol — tenormin I. C. I. — a new beta-adrenergic blocker. Br. J. Ophthalmol. 59, 196(1975).

    Article  Google Scholar 

  5. Bucci, M. G., Missiroli, A., Giraldi, J.: Local administration of propranolol in the treatment of glaucoma. Boll. Oculist. 47, 51–60 (1968).

    PubMed  CAS  Google Scholar 

  6. Ros, F. E., Dake, C. L., Nagelkerke, N. J. D., Greve, E. L.: Metoprolol eye drops in the treatment of glaucoma. A double-blind single dose trial of a betai-adrenergic blocking drug. Graefes Arch. Klin. Exp. Ophthalmol. 206, 247–254 (1978).

    Article  CAS  Google Scholar 

  7. Bonomi, L., Perfetti, S., Noya, E., Bellucci, R., Massa, F.: Comparison of the effect of nine beta-adrenergic blocking agents on intraocular pressure in rabbits. Graefes Arch. Klin. Exp. Ophthalmol. 210, 1–8 (1979).

    Google Scholar 

  8. Katz, L M.: Beta-blockers and the eye. An overview. Ann. Ophthalmol. 10, 847–850 (1978).

    PubMed  CAS  Google Scholar 

  9. Leydhecker, W.: Sympathikomimetika und Sympathikolytika in der Glaukomtherapie. Klin. Mbl. Augenheilk. 171, 538–546 (1977).

    Google Scholar 

  10. Nielsen, N. V.: Timolol und Metoprolol. Okulärer hypotensiver Effekt, lokale und systemische Begleiteffekte. Z. prakt. Augenheilk. 2, 71–77 (1981).

    CAS  Google Scholar 

  11. Krieglstein, G. K., Leydhecker, W.: Medikamentöse Glaukomtherapie. München: Bergmann. 1982.

    Google Scholar 

  12. Kern, R.: Zur Verteilung der adrenergen Rezeptoren im M. sphincter pupillae, im M. dilatator pupillae und im Ziliarkörper des Menschen; deren Bedeutung bei der Behandlung der Hypotonia bulbi und des Glaukoms. In: Medikamentöse Glaukomtherapie (Krieglstein, G. K., Leydhecker, W., Hrsg.), S. 133 ff. München: Bergmann. 1982.

    Google Scholar 

  13. Sears, M. L., Barany, E. H.: Outflow resistance and adrenergic mechanisms. Effects of sympathectomy, N-(2-chloroethyl)dibenzylamine hydrochloride (dibenamine), and dichloroisoproterenol on the outflow resistance of the rabbit eye. Arch. Ophthalmol. 64, 839–848 (1960).

    Article  PubMed  CAS  Google Scholar 

  14. Takase, M.: Effects of propranolol on aqueous dynamics in primary openangle glaucoma. Acta Soc. Ophthalmol. Jpn.80, 310–314 (1976).

    CAS  Google Scholar 

  15. Potter, D. E.: Adrenergic pharmacology of aqueous humor dynamics. Pharmacol. Review 33, 133–153 (1981).

    CAS  Google Scholar 

  16. Vareilles, P., Lotti, V. J.: Effect of timolol on aqueous humor dynamics in the rabbit. Ophthalmic Res. 13, 72–79 (1981).

    Article  CAS  Google Scholar 

  17. Cruickshank, J. M.: The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am. Heart J. 100, 160–178 (1980).

    Article  PubMed  CAS  Google Scholar 

  18. Takats, I., Szilvassy, L, Kerek, A.: Intraocularer Druck und Kammer- wasserzirkulationsuntersuchungen an Kaninchenaugen nach intravenöser Verabreichung von Propranolol (Inderal). Graefes Arch. Klin. Exp. Ophthalmol. 185, 331–342 (1972).

    Article  CAS  Google Scholar 

  19. Öhrström, A., Kättström, Ö.: Interaction of timolol and adrenaline. Br. J. Ophthalmol. 65, 53–55 (1981).

    Article  PubMed  Google Scholar 

  20. Innemee, H. C., De Jonge, A., Van Meel, J. C. A., Timmermanns, P. B. M., Van Zwieten, P. A.: The effect of selective ai- and a2-adreno- ceptor stimulation on intraocular pressure in the conscious rabbit. Naunyn-Schmiedebergs Arch. Pharmacol. 316, 294–298 (1981).

    Article  PubMed  CAS  Google Scholar 

  21. Neufeld, A. H., Page, E. D.: In vitro determination of the ability of drugs to bind to adrenergic receptors. Invest. Ophthalmol. Visual Sci. 16, 1118–1124 (1977).

    CAS  Google Scholar 

  22. Mittag, T., Tormay, A.: Adrenergic receptors in iris-ciliary body: direct ligand binding studies. Invest. Ophthalmol. Visual Sci. (A. R. V. O. suppl.) 20, 198 (1981).

    Google Scholar 

  23. Dafna, Z., Lahav, M., Melamad, E.: Localization of beta-adrenoceptors in the anterior segment of the albino rabbit eye using a fluorescent analog of propranolol. Exp. Eye Res. 29, 327–330 (1979).

    Article  PubMed  CAS  Google Scholar 

  24. Bromberg, B. B., Gregory, D. S., Sears, M. L.: Beta-adrenergic receptors in ciliary processes of the rabbit. Invest. Ophthalmol. Visual Sci. 19, 203–207 (1980).

    CAS  Google Scholar 

  25. Nathanson, J. A.: Effects of a potent and specific /Sa-adrenoceptor antagonist on intraocular pressure. Br. J. Pharmacol. 73, 91–100 (1981).

    Google Scholar 

  26. Thomas, J. V.: Ocular adrenergic receptor sites pertinent to aqueous humor dynamics. Ann. Ophthalmol. 12, 96–98 (1980).

    Google Scholar 

  27. Pentikäinen, P. J., Neuvonen, P. J., Penttila, A.: Assessment of beta- blocking activity of trimepranol in man. Int. J. Clin. Pharmacol. 6, 279–284 (1978).

    Google Scholar 

  28. Zakhari, S., Pronay, N., Drimal, J., Molnar, L.: Correlations between the partition coefficient and the beta-adrenolytic activities of trimepranol and its analogues. Bratislavske lekafske Listy 62, 678–688 (1974).

    Google Scholar 

  29. Bieth, N., Rouot, B., Schwärzt, J., Velly, J.: Comparison of pharmacological and binding assays for ten β-adrenoceptor blocking agents and two β-adrenoceptor agonists. Br. J. Pharmacol. 68, 563–569 (1980).

    PubMed  CAS  Google Scholar 

  30. Dreyer, A. C., Offermeier, J.: In vitro assessment of the selectivities of various beta-adrenergic blocking agents. Life Sci. 27, 2087–2098 (1980).

    Article  PubMed  CAS  Google Scholar 

  31. Kaumann, A. J., Mclnerny, T. K., Gilmour, D. P., Blinks, J. R.: Comparative assessment of β-adrenoceptor blocking agents as simple competitive agonists in isolated heart muscle. Naunyn-Schmiedebergs Arch. Pharmacol. 311, 219–236 (1980).

    Article  PubMed  CAS  Google Scholar 

  32. Noack, E.: Untersuchungen zur spezifisch adrenolytischen und unspezifisch kardiodepressiven Wirkung des β-Rezeptorenblockers Acebutolol. Arzneim.-Forsch./Drug Res. 31, 1410–1416 (1981).

    CAS  Google Scholar 

  33. Colasanti, B. K., Trotter, R. R.: Effects of selective betai- and beta2- adrenoceptor agonists and antagonists on intraocular pressure in the cat. Invest. Ophthalmol. Vis. Sci. 20, 69–76 (1981).

    PubMed  CAS  Google Scholar 

  34. Demmler, N.: Beta-Rezeptorenblocker in der Ophthalmologie. Med. Mo. Pharm. 3, 174–179 (1980).

    CAS  Google Scholar 

  35. Bartsch, W., Sponer, G., Dietmann, K.: Experiments in animals on the pharmacological effects of metipranolol in comparison with propranolol and pindolol. Arzneim.-Forsch./Drug Res. 27, 2319–2322 (1977)

    CAS  Google Scholar 

  36. Trčka, V.: Pharmacological activities of trimepranol and its fate in the organism. Part 2. Res. Institute for Pharmacy and Biochem., Prague, 1973.

    Google Scholar 

  37. Hopf, R., Tourbier, H., Kaltenbach, M.: Wirksamkeit des Beta-Sym- pathikolytikums Methypranolol auf Belastungsherzfrequenz und ischämische ST-Senkung im Vergleich mit Plazebo und Propranolol. Herz/ Kreislauf 9, 560–565 (1977).

    CAS  Google Scholar 

  38. Cocan, D. G., Hirsch, E. D.: The cornea, VII. Permeability to weak electrolytes. Arch. Pharmacol. 32, 276–282 (1944).

    Google Scholar 

  39. Swan, K. €., White, N. G.: Corneal permeability, I. Sectors effecting penetration of drugs into the cornea. Am. J. Ophthalmol. 25, 1043–1058 (1942).

    Google Scholar 

  40. Schmitt, C. J., Lotti, V. J., Le Duarec, J. C.: Penetration of timolol into the rabbit eye. Measurement after ocular installation and intravenous injection. Arch. Ophthalmol. 95, 547–551 (1980).

    Article  Google Scholar 

  41. Ros, F. E., Innemee, H. C., Van Zwieten, P. A.: Penetration of atenolol in the rabbit eye. Graefes Arch. Klin. Exp. Ophthalmol. 108, 235–240 (1978).

    Article  Google Scholar 

  42. Hellenbrecht, D., Lemmer, B., Wiethold, G., et al, Measurement of hydrophobicity, surface activity, local anaesthesis and myocardical conduction velocity as quantitative parameters of the non-specific membrane affinity of nine β-adrenergic blocking agents. Naunyn- Schmiedebergs Arch. Pharmacol. 277, 211–226 (1973).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie, Universität Düsseldorf, Moorenstraße 5, D-4000, Düsseldorf 1, Bundesrepublik Deutschland

    Prof. Dr. E. A. Noack

Authors
  1. Prof. Dr. E. A. Noack
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Augenklinik und -poliklinik, Klinikum rechts der Isar, München, Bundesrepublik Deutschland

    Hanns-Jürgen Merté (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 1983 Springer-Verlag/Wien

About this chapter

Cite this chapter

Noack, E.A. (1983). Eignung von Metipranolol für die Therapie des Glaukoms aus pharmakologischer Sicht. In: Merté, HJ. (eds) Metipranolol. Springer, Vienna. https://doi.org/10.1007/978-3-7091-8709-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-8709-8_5

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-8710-4

  • Online ISBN: 978-3-7091-8709-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation